156 related articles for article (PubMed ID: 26872429)
1. Reduced DPP4 activity improves insulin signaling in primary human adipocytes.
Röhrborn D; Brückner J; Sell H; Eckel J
Biochem Biophys Res Commun; 2016 Mar; 471(3):348-54. PubMed ID: 26872429
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Lamers D; Famulla S; Wronkowitz N; Hartwig S; Lehr S; Ouwens DM; Eckardt K; Kaufman JM; Ryden M; Müller S; Hanisch FG; Ruige J; Arner P; Sell H; Eckel J
Diabetes; 2011 Jul; 60(7):1917-25. PubMed ID: 21593202
[TBL] [Abstract][Full Text] [Related]
3. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2.
Wronkowitz N; Görgens SW; Romacho T; Villalobos LA; Sánchez-Ferrer CF; Peiró C; Sell H; Eckel J
Biochim Biophys Acta; 2014 Sep; 1842(9):1613-21. PubMed ID: 24928308
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.
Chowdhury HH; Velebit J; Radić N; Frančič V; Kreft M; Zorec R
J Diabetes Res; 2016; 2016():7481470. PubMed ID: 26881257
[TBL] [Abstract][Full Text] [Related]
5. Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes.
Zilleßen P; Celner J; Kretschmann A; Pfeifer A; Racké K; Mayer P
Sci Rep; 2016 Mar; 6():23074. PubMed ID: 26983599
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
Chen Z; Yu J; Fu M; Dong R; Yang Y; Luo J; Hu S; Li W; Xu X; Tu L
Biochem Pharmacol; 2020 Jul; 177():113951. PubMed ID: 32251672
[TBL] [Abstract][Full Text] [Related]
7. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Kim MK; Chae YN; Kim HD; Yang EK; Cho EJ; Choi SH; Cheong YH; Kim HS; Kim HJ; Jo YW; Son MH; Kim SH; Shin CY
Life Sci; 2012 Jan; 90(1-2):21-9. PubMed ID: 22056373
[TBL] [Abstract][Full Text] [Related]
8. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Huang H; Shetty S; Bauer E; Lang K
Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
Baggio LL; Varin EM; Koehler JA; Cao X; Lokhnygina Y; Stevens SR; Holman RR; Drucker DJ
Nat Commun; 2020 Jul; 11(1):3766. PubMed ID: 32724076
[TBL] [Abstract][Full Text] [Related]
10. DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity.
Romacho T; Sell H; Indrakusuma I; Roehrborn D; Castañeda TR; Jelenik T; Markgraf D; Hartwig S; Weiss J; Al-Hasani H; Roden M; Eckel J
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E590-E599. PubMed ID: 31891536
[TBL] [Abstract][Full Text] [Related]
11. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells.
Röhrborn D; Eckel J; Sell H
FEBS Lett; 2014 Nov; 588(21):3870-7. PubMed ID: 25217834
[TBL] [Abstract][Full Text] [Related]
12. Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance.
Ahmed RH; Huri HZ; Muniandy S; Al-Hamodi Z; Al-Absi B; Alsalahi A; Razif MF
Clin Biochem; 2017 Sep; 50(13-14):746-749. PubMed ID: 28288852
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
Huan Y; Jiang Q; Liu JL; Shen ZF
J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Ghorpade DS; Ozcan L; Zheng Z; Nicoloro SM; Shen Y; Chen E; Blüher M; Czech MP; Tabas I
Nature; 2018 Mar; 555(7698):673-677. PubMed ID: 29562231
[TBL] [Abstract][Full Text] [Related]
15. Role of dipeptidyl peptidase-4 as a potentiator of activin/nodal signaling pathway.
Park DS; Kim K; Jang M; Choi SC
BMB Rep; 2018 Dec; 51(12):636-641. PubMed ID: 30463640
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.
Mason RP; Jacob RF; Kubant R; Ciszewski A; Corbalan JJ; Malinski T
J Cardiovasc Pharmacol; 2012 Nov; 60(5):467-73. PubMed ID: 22932707
[TBL] [Abstract][Full Text] [Related]
17. The lysyl oxidase inhibitor β-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats.
Miana M; Galán M; Martínez-Martínez E; Varona S; Jurado-López R; Bausa-Miranda B; Antequera A; Luaces M; Martínez-González J; Rodríguez C; Cachofeiro V
Dis Model Mech; 2015 Jun; 8(6):543-51. PubMed ID: 26035864
[TBL] [Abstract][Full Text] [Related]
18. Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis.
Baerts L; Glorie L; Maho W; Eelen A; Verhulst A; D'Haese P; Covaci A; De Meester I
Pharmacol Res; 2015 Oct; 100():336-40. PubMed ID: 26342756
[TBL] [Abstract][Full Text] [Related]
19. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
Kawaguchi M; Okabe T; Terai T; Hanaoka K; Kojima H; Minegishi I; Nagano T
Chemistry; 2010 Dec; 16(45):13479-86. PubMed ID: 20938933
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibition prevents vascular dysfunction induced by β-adrenergic hyperactivity.
Oliveira BC; Marques VB; Brun BF; de Oliveira E Silva HM; Freitas Soares Melo S; Oliveira EM; Dos Santos L; Barauna VG
Biomed Pharmacother; 2019 May; 113():108733. PubMed ID: 30861410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
